Non-Hodgkin's lymphoma of the Waldeyer's ring

the treatment results of the past 22 years and the significance of CHOP

H. Hiramatsu, M. Kondo, M. Uematsu, Naoyuki Shigematsu, Y. Ando, S. Hashimoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

From 1966 through 1988, 124 patients with non-Hodgkin's lymphoma of the Waldeyer's ring were treated. Seventy patients were male, and 54 were female. Age ranged from 5 to 81 years with a median value of 53 years. Pathological slides were reviewed and reclassified according to the Working Formulation. Diffuse large cell type was most common (53%). Since 1981, CHOP has been incorporated into the treatment including stage I and II patients. During these 22 years, new imaging modalities have developed, and an upstage rate by using those modalities has increased from 5% to 9%. In order to make the comparison meaningful, we used clinical stage determined at the day of the first visit. Fifty-one patients were clinical stage I, 64 were stage II, seven were stage III, and two were stage IV. B symptom was seen in 8 patients. Relapse developed in 45 patients (41%) out of 111 who achieved complete remission, and distant relapse was most frequent (89%). Salvage therapy was successful in only three patients of the 45 relapsed patients. Overall 5-year freedom from relapse (FFR) were 38% for the patients treated until 1980, and 69% for the patients treated thereafter (p less than 0.01). Addition of CHOP to radiotherapy has increased 5-year FFR of the stage II patients from 31% to 81% (p less than 0.01). In stage I, 5-year FFR was 71% in the patients treated with CHOP and radiotherapy, and it was 27% treated without CHOP. But the difference has no statistical significance, and we can not rule out the presence of selection bias.(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageEnglish
Pages (from-to)2477-2483
Number of pages7
JournalJournal of Japan Society for Cancer Therapy
Volume25
Issue number10
Publication statusPublished - 1990 Oct 20

Fingerprint

Non-Hodgkin's Lymphoma
Recurrence
Therapeutics
Radiotherapy
Salvage Therapy
Selection Bias

ASJC Scopus subject areas

  • Cancer Research

Cite this

Non-Hodgkin's lymphoma of the Waldeyer's ring : the treatment results of the past 22 years and the significance of CHOP. / Hiramatsu, H.; Kondo, M.; Uematsu, M.; Shigematsu, Naoyuki; Ando, Y.; Hashimoto, S.

In: Journal of Japan Society for Cancer Therapy, Vol. 25, No. 10, 20.10.1990, p. 2477-2483.

Research output: Contribution to journalArticle

@article{628ebb92b4204a4b990a7e1272ed09be,
title = "Non-Hodgkin's lymphoma of the Waldeyer's ring: the treatment results of the past 22 years and the significance of CHOP",
abstract = "From 1966 through 1988, 124 patients with non-Hodgkin's lymphoma of the Waldeyer's ring were treated. Seventy patients were male, and 54 were female. Age ranged from 5 to 81 years with a median value of 53 years. Pathological slides were reviewed and reclassified according to the Working Formulation. Diffuse large cell type was most common (53{\%}). Since 1981, CHOP has been incorporated into the treatment including stage I and II patients. During these 22 years, new imaging modalities have developed, and an upstage rate by using those modalities has increased from 5{\%} to 9{\%}. In order to make the comparison meaningful, we used clinical stage determined at the day of the first visit. Fifty-one patients were clinical stage I, 64 were stage II, seven were stage III, and two were stage IV. B symptom was seen in 8 patients. Relapse developed in 45 patients (41{\%}) out of 111 who achieved complete remission, and distant relapse was most frequent (89{\%}). Salvage therapy was successful in only three patients of the 45 relapsed patients. Overall 5-year freedom from relapse (FFR) were 38{\%} for the patients treated until 1980, and 69{\%} for the patients treated thereafter (p less than 0.01). Addition of CHOP to radiotherapy has increased 5-year FFR of the stage II patients from 31{\%} to 81{\%} (p less than 0.01). In stage I, 5-year FFR was 71{\%} in the patients treated with CHOP and radiotherapy, and it was 27{\%} treated without CHOP. But the difference has no statistical significance, and we can not rule out the presence of selection bias.(ABSTRACT TRUNCATED AT 250 WORDS)",
author = "H. Hiramatsu and M. Kondo and M. Uematsu and Naoyuki Shigematsu and Y. Ando and S. Hashimoto",
year = "1990",
month = "10",
day = "20",
language = "English",
volume = "25",
pages = "2477--2483",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "10",

}

TY - JOUR

T1 - Non-Hodgkin's lymphoma of the Waldeyer's ring

T2 - the treatment results of the past 22 years and the significance of CHOP

AU - Hiramatsu, H.

AU - Kondo, M.

AU - Uematsu, M.

AU - Shigematsu, Naoyuki

AU - Ando, Y.

AU - Hashimoto, S.

PY - 1990/10/20

Y1 - 1990/10/20

N2 - From 1966 through 1988, 124 patients with non-Hodgkin's lymphoma of the Waldeyer's ring were treated. Seventy patients were male, and 54 were female. Age ranged from 5 to 81 years with a median value of 53 years. Pathological slides were reviewed and reclassified according to the Working Formulation. Diffuse large cell type was most common (53%). Since 1981, CHOP has been incorporated into the treatment including stage I and II patients. During these 22 years, new imaging modalities have developed, and an upstage rate by using those modalities has increased from 5% to 9%. In order to make the comparison meaningful, we used clinical stage determined at the day of the first visit. Fifty-one patients were clinical stage I, 64 were stage II, seven were stage III, and two were stage IV. B symptom was seen in 8 patients. Relapse developed in 45 patients (41%) out of 111 who achieved complete remission, and distant relapse was most frequent (89%). Salvage therapy was successful in only three patients of the 45 relapsed patients. Overall 5-year freedom from relapse (FFR) were 38% for the patients treated until 1980, and 69% for the patients treated thereafter (p less than 0.01). Addition of CHOP to radiotherapy has increased 5-year FFR of the stage II patients from 31% to 81% (p less than 0.01). In stage I, 5-year FFR was 71% in the patients treated with CHOP and radiotherapy, and it was 27% treated without CHOP. But the difference has no statistical significance, and we can not rule out the presence of selection bias.(ABSTRACT TRUNCATED AT 250 WORDS)

AB - From 1966 through 1988, 124 patients with non-Hodgkin's lymphoma of the Waldeyer's ring were treated. Seventy patients were male, and 54 were female. Age ranged from 5 to 81 years with a median value of 53 years. Pathological slides were reviewed and reclassified according to the Working Formulation. Diffuse large cell type was most common (53%). Since 1981, CHOP has been incorporated into the treatment including stage I and II patients. During these 22 years, new imaging modalities have developed, and an upstage rate by using those modalities has increased from 5% to 9%. In order to make the comparison meaningful, we used clinical stage determined at the day of the first visit. Fifty-one patients were clinical stage I, 64 were stage II, seven were stage III, and two were stage IV. B symptom was seen in 8 patients. Relapse developed in 45 patients (41%) out of 111 who achieved complete remission, and distant relapse was most frequent (89%). Salvage therapy was successful in only three patients of the 45 relapsed patients. Overall 5-year freedom from relapse (FFR) were 38% for the patients treated until 1980, and 69% for the patients treated thereafter (p less than 0.01). Addition of CHOP to radiotherapy has increased 5-year FFR of the stage II patients from 31% to 81% (p less than 0.01). In stage I, 5-year FFR was 71% in the patients treated with CHOP and radiotherapy, and it was 27% treated without CHOP. But the difference has no statistical significance, and we can not rule out the presence of selection bias.(ABSTRACT TRUNCATED AT 250 WORDS)

UR - http://www.scopus.com/inward/record.url?scp=0025711675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025711675&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 2477

EP - 2483

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 10

ER -